Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
David Straus MD

David J. Straus MD

Attending Physician, Lymphoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York

Dr. David Straus is an attending physician on the Lymphoma Service in the Department of Medicine at Memorial Sloan-Kettering Cancer Center in New York. He has had a large clinical practice for more than 30 years, treating patients with malignant lymphomas, chronic lymphocytic leukemia, and multiple myeloma. His longstanding clinical research interests focus on malignant lymphomas, and he has authored more than 150 publications on this topic. Dr. Straus has conducted clinical trials in Hodgkin’s lymphoma, cutaneous T-cell lymphomas, and HIV-associated lymphomas, as well as studies assessing quality of life and survivorship issues in patients with lymphoma.

Recent Contributions to PracticeUpdate:

  1. ASCO 2021: Abstract Recommendations From Dr. David Straus for Hematologic Malignancies
  2. Autologous Stem Cell Transplantation After Anti–PD-1 Therapy for Multiply Relapsed or Refractory Hodgkin Lymphoma
  3. PET-Guided Omission of Radiotherapy in Early-Stage Unfavourable Hodgkin Lymphoma
  4. Pembrolizumab Followed by AVD in Untreated Early Unfavorable and Advanced-Stage Classical Hodgkin Lymphoma
  5. ASCO 2020: Abstract Recommendations From Dr. David Straus for Hematologic Malignancies
  6. Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma
  7. PET-Guided Treatment in Early-Stage Favorable Hodgkin's Lymphoma
  8. Ibrutinib + Lenalidomide and Rituximab Is Promising in Relapsed/Refractory Non–Germinal Center B-Cell DLBCL
  9. ASCO 2019: Abstract Recommendations From Dr. David Straus for Lymphoma
  10. PD-1 Blockade With Pembrolizumab for Classical Hodgkin's Lymphoma After ASCT

Most Read This Week

Recently Updated